MDS Diagnosis Using cfRNA Profiling By Targeted Enrichment Next Generation Sequencing Read more about MDS Diagnosis Using cfRNA Profiling By Targeted Enrichment Next Generation Sequencing
IDH1 and IDH2: founding or progressor mutations in myeloid neoplasms Read more about IDH1 and IDH2: founding or progressor mutations in myeloid neoplasms
Association between microsatellite instability and BRAF, TP53, PTEN, and KRAS mutations in colorectal cancer Read more about Association between microsatellite instability and BRAF, TP53, PTEN, and KRAS mutations in colorectal cancer
Comparison of diagnostic methodologies to detect chromosomal abnormalities. Read more about Comparison of diagnostic methodologies to detect chromosomal abnormalities.
Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project Read more about Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project
Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study Read more about Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study
Role of epigenetic regulators in Single Base Substitution patterns in AML Read more about Role of epigenetic regulators in Single Base Substitution patterns in AML
Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC) Read more about Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
ctDNA detection in early-stage non-small cell lung cancer Read more about ctDNA detection in early-stage non-small cell lung cancer
Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC) Read more about Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)